Assessment of anti-inflammatory and antioxidant activity of quercetin-rutin blend (SophorOx™)- an invitro cell based assay.

Abstract

Quercetin & Rutin, are bioactive compounds that are widely used for various therapeutic properties. There's been growing interest in the biological activities of these polyphenols belonging to the class of flavonoids known to have various health benefits. Quercetin is now popularly recognized as a phytochemical remedy for a plethora of disease groups such as metabolic syndrome (more specifically diabetes), obesity/weight management and mood disorders. Due to its unique chemical structure, the most prominent property of Quercetin is probably itsantioxidant capability. It acts as a free radical scavenger to form resonance-stabilized phenoxyl radicals. Certain in vitro studies have also shown quercetin to have anti-viral, anti-carcinogenic and platelet aggregation properties. Rutin has also been shown to exert diverse biological effects such as anti-tumor activities, reduction of inflammatory cytokines and antimicrobial activities. The current study was designed to further confirm the antioxidant and anti-inflammatory property of a Quercetin-Rutin blend (SophorOx™). The analysis was performed in a cell-based assay using RAW 264.7 macrophage cell line. SophorOx™ was screened for cytotoxicity using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) to obtain optimum concentrations for experimental assays. SophorOx™ was measured for pro-inflammatory cytokine levels (TNF-α & IL-6) and nitric oxide (NO) levels. Additionally, ROS (reactive oxygen species) levels in RAW cells were estimated using a cell-permeant reagent 2'7'-dichlorofluorescein diacetate (DCFH-DA). SophorOx™ at 10µM concentration, exhibited an anti-inflammatory property with significant inhibitory levels of TNF-α (∼28.25%) and IL-6 (∼32.25%). SophorOx™ at similar concentrations reduced nitric oxide levels to 70.55% in lipopolysaccharide (LPS) stimulated RAW 264.7 cells. Raw 264.7 cells stimulated with LPS exhibited a significant increase in intracellular ROS and this was significantly reduced (78.2% reduction) at lower concentrations (0.3 µM) of SophorOx™. The anti-inflammatory effects of SophorOx™ were investigated in LPS stimulated RAW 264.7 macrophages. Data suggests, that SophorOx™ reduced levels of nitric oxide, intracellular ROS and pro-inflammatory cytokines (TNF-α & IL-6) at low concentrations without affecting the viability of RAW cells. Present invitro trial suggests that SophorOx™ is a potent antioxidant and anti-inflammatory agent and displays a prominent ability to block mediators of oxidative stress and inflammation.